Why the study?
Recombinant B38-CAP is prepared more efficiently than recombinant soluble human ACE2, prompting evaluation of its therapeutic effects on abdominal sepsis- or acid aspiration-induced acute lung injury.
Does intraperitoneal injection of the ACE2-like enzyme B38-CAP improve survival and reduce lung injury in mice with abdominal sepsis or acid aspiration-induced acute lung injury?
Does intraperitoneal injection of the ACE2-like enzyme B38-CAP improve survival and reduce lung injury in mice with abdominal sepsis or acid aspiration-induced acute lung injury?
B38-CAP, a bacteria-derived ACE2-like enzyme, improves survival and attenuates severe acute lung injury in murine models of sepsis and acid aspiration by downregulating Angiotensin II.
Answers are grounded in this paper and cite their sources.
B38-CAP merits clinical investigation in cardiovascular and lung disease; leaves open its role pending human trials.
Angiotensin-converting enzyme 2 (ACE2) is the carboxypeptidase to degrade angiotensin II (Ang II) to angiotensin 1-7 (Ang 1-7) and improves the pathologies of cardiovascular disease and acute respiratory distress syndrome (ARDS)/acute lung injury. B38-CAP is a bacteria-derived ACE2-like carboxypeptidase as potent as human ACE2 and ameliorates hypertension, heart failure and SARS-CoV-2-induced lung injury in mice. Recombinant B38-CAP is prepared with E. coli protein expression system more efficiently than recombinant soluble human ACE2. Here we show therapeutic effects of B38-CAP on abdominal sepsis- or acid aspiration-induced acute lung injury. ACE2 expression was downregulated in the lungs of mice with cecal ligation puncture (CLP)-induced sepsis or acid-induced lung injury thereby leading to upregulation of Ang II levels. Intraperitoneal injection of B38-CAP significantly decreased Ang II levels while upregulated angiotensin 1-7 levels. B38-CAP improved survival rate of the mice under sepsis. B38-CAP suppressed the pathologies of lung inflammation, improved lung dysfunction and downregulated elevated cytokine mRNA levels in the mice with acute lung injury. Thus, systemic treatment with an ACE2-like enzyme might be a potential therapeutic strategy for the patients with severe sepsis or ARDS.
No takes yet. Share an insight, caveat, or question.
Minato et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: